| Dr Jennifer Pascual, MD | |
|
1 General St, Lawrence, MA 01841 | |
| (978) 683-4000 | |
| Not Available |
| Full Name | Dr Jennifer Pascual |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 10 Years |
| Location | 1 General St, Lawrence, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356755136 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 274948 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Massachusetts General Hospital | Boston, MA | Hospital |
| Martha's Vineyard Hospital Inc | Oak bluffs, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Massachusetts General Physicians Organization Inc | 2466365820 | 3085 |
News Archive
GastroFISH™ is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.
A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia.
Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.
Mesenchymal stem cells (MSCs) are bone marrow-derived cells that are capable of giving rise to various cell types through a process known as differentiation.
› Verified 3 days ago
| Entity Name | Massachusetts General Physicians Organization Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801874573 PECOS PAC ID: 2466365820 Enrollment ID: O20031111000434 |
News Archive
GastroFISH™ is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.
A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia.
Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.
Mesenchymal stem cells (MSCs) are bone marrow-derived cells that are capable of giving rise to various cell types through a process known as differentiation.
› Verified 3 days ago
| Entity Name | Martha's Vineyard Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194866210 PECOS PAC ID: 9931166113 Enrollment ID: O20041220000589 |
News Archive
GastroFISH™ is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.
A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia.
Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.
Mesenchymal stem cells (MSCs) are bone marrow-derived cells that are capable of giving rise to various cell types through a process known as differentiation.
› Verified 3 days ago
| Entity Name | North Shore Physicians Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588606123 PECOS PAC ID: 3577467224 Enrollment ID: O20050429000668 |
News Archive
GastroFISH™ is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.
A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia.
Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.
Mesenchymal stem cells (MSCs) are bone marrow-derived cells that are capable of giving rise to various cell types through a process known as differentiation.
› Verified 3 days ago
| Entity Name | The General Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023049236 PECOS PAC ID: 6507803806 Enrollment ID: O20080313000351 |
News Archive
GastroFISH™ is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.
A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia.
Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.
Mesenchymal stem cells (MSCs) are bone marrow-derived cells that are capable of giving rise to various cell types through a process known as differentiation.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Pascual, MD 1 General St, Lawrence, MA 01841-2997 Ph: (978) 683-4000 | Dr Jennifer Pascual, MD 1 General St, Lawrence, MA 01841 Ph: (978) 683-4000 |
News Archive
GastroFISH™ is the first tissue-based fluorescence in situ hybridization (FISH) test for the detection of chromosomal anomalies associated with colon cancer.
A Lancet editorial discusses the agenda of the XIX International AIDS Conference (AIDS 2012) in Washington last month and asks how the success of the conference will be judged at the XX International AIDS Conference (AIDS 2014), to be held in Melbourne, Australia.
Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.
Mesenchymal stem cells (MSCs) are bone marrow-derived cells that are capable of giving rise to various cell types through a process known as differentiation.
› Verified 3 days ago
Dr. Franklin D. Friedman, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 General St, Anne Mottram- Administrative Secretary, Lawrence, MA 01841 Phone: 978-683-4000 Fax: 978-946-8026 | |
Dr. Igor Stavitsky, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 General St, Andrea Sullivan-director Of Managed Care Dept.., Lawrence, MA 01841 Phone: 978-683-4000 Fax: 978-946-8017 | |
Anand Gopalan Nataraj, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 General St, Lawrence, MA 01841 Phone: 978-683-4000 | |
Dr. Mary Lynn Joe, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 360 Merrimack St, Lawrence, MA 01843 Phone: 978-557-8800 Fax: 978-557-8633 | |
Dr. Timothy Chu, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 General St, Lawrence General Hospital, Lawrence, MA 01841 Phone: 617-835-4699 | |
Dr. James L. Schaepe, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 General St, Andrea Sullivan-director Of Managed Care Dept., Lawrence, MA 01841 Phone: 978-683-4000 Fax: 978-946-8017 | |
Dr. John W. Lucas, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1 General St, Andrea Sullivan-director Of Managed Care Dept., Lawrence, MA 01841 Phone: 978-683-4000 Fax: 978-946-8017 |